Effects of GDHT (Goal Directed Hemodynamic Therapy) Using a Non-invasive Hemodynamic Monitoring in Elective Neurosurgery
Ориентир для пациента и семьи
Простыми словами
Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.
- Что изучают
- В протоколе указаны: Standard monitoring, Goal-Directed Therapy.
- Кому может быть актуально
- Состояния в реестре: Surgery Complications. Базовые параметры: от 18 лет · Все.
- Что важно проверить
- Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
- Где проводится
- Список центров уточняется — проверьте первичный протокол.
- Следующий шаг
- Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Не всё понятно в терминах? Прочитайте наш гид для пациентов →
Официальное название
Effects of Goal-directed Fluid Management Guided by a Non-invasive Device on the Incidence of Postoperative Complications in Neurosurgery: a Multicenter, Prospective, Randomized, Controlled Study
Обзор
This study aims to assess the safety and efficacy of GDHT using the non-invasive Starling™ SV System in elective neurosurgery. The tested group of patients (n=70) will be compared with a control group (n=70), where hemodynamic management will be guided by standard vital signs monitoring.
Подробное описание
Patients undergoing major surgery are at risk for inadequate intravascular volumes and therefore inadequate tissue perfusion and oxygen delivery. Especially in neurosurgery, fluid management can be a challenge. In many surgical areas, such as orthopedics, gynecology or abdominal surgery, goal-directed fluid therapy is used with the aim of reducing postoperative complications. Current knowledge regarding effect of the goal-directed therapy in neurosurgery is limited.
This is a multicenter, prospective, randomized, controlled study that compares two approaches to fluid management in elective brain surgery. Patients scheduled for brain surgery will be screened whether they meet the inclusion criteria and after obtaining informed consent, the patient will be randomized to one of two study arms.
In the first (standard) arm standard vital signs monitoring will be used during the surgery and perioperative fluid management and administration of vasopressors will be guided by the decision of the attending anaesthetist.
In the second (GDT) arm perioperative fluid management and administration of vasopressors will be guided by a non-invasive hemodynamic monitor STARLINK™SV, which will be introduced in addition to standard monitoring.
The primary outcome is the incidence of adverse events and reactions according to following Adverse Events of Special Interest (AESI) in both study groups and their comparison. The secondary outcome is to investigate the efficacy and additional safety parameters of GDHT guided by non-invasive advanced hemodynamic monitoring versus hemodynamic management guided by standard vital signs monitoring.
This study will enroll 140 patients in total, 70 in each group. After completion of enrolment of patients the statistical analysis will be performed.
Вмешательства
- Другое Standard monitoring
Administration of fluids and vasoactive drugs guided by standard vital signs monitoring - Другое Goal-Directed Therapy
Administration of fluids and vasoactive drugs guided by non-invasive haemodynamic monitoring
Первичные конечные точки
- Number of participants with acute kidney Injury [Срок оценки: 28 days]
- Number of participants with acute Respiratory Distress Syndrome (ARDS) [Срок оценки: 28 days]
- Number of participants with arrhythmia [Срок оценки: 28 days]
- Number of participants with cardiac arrest [Срок оценки: 28 days]
- Number of participants with cardiogenic pulmonary oedema [Срок оценки: 28 days]
- Number of participants with deep vein thrombosis (DVT) [Срок оценки: 28 days]
- Number of participants with pulmonary embolism (PE) [Срок оценки: 28 days]
- Number of participants with gastrointestinal bleed [Срок оценки: 28 days]
- Number of participants with infection, source uncertain [Срок оценки: 28 days]
- Number of participants with laboratory confirmed bloodstream infection [Срок оценки: 28 days]
Вторичные конечные точки (12)
- Duration of surgery [Срок оценки: During the surgery (hours)]
- Length of hospital stay [Срок оценки: Days (up to 28)]
- ICU length of stay [Срок оценки: Days (up to 28)]
- 28-day mortality [Срок оценки: 28 days after randomization]
- Adverse events [Срок оценки: 28 days]
- Hemodynamic characteristics - MAP (Mean arterial pressure) [Срок оценки: During the surgery and 24 hours post operation]
- Hemodynamic characteristics - HR (Heart rate) [Срок оценки: During the surgery and 24 hours post operation]
- Hemodynamic characteristics - SVV (Stroke volume variation) measured by The Starling™ SV System [Срок оценки: During the surgery (hours)]
- Hemodynamic characteristics - number of episodes of hypotension [Срок оценки: During the surgery and 24 hours post operation]
- Hemodynamic characteristics - number of vasopressor administrations [Срок оценки: During the surgery and 24 hours post operation]
- Hemoglobin [Срок оценки: 24 hours]
- Plasma lactate level [Срок оценки: 24 hours]
Критерии участия
Критерии включения
Subjects will be eligible for the trial if they meet all of the following criteria:
- Age ≥ 18 years
- Elective brain surgery with an expected duration ≥ 2 h
- Category 1-3 according to the ASA (American Society of Anesthesiologists) Physical Status Classification
- Lateral or supine operative position
- Signed the relevant informed consent form
Критерии исключения
Subjects will not be eligible for the trial if they meet any of the following criteria:
- Category 4 according to the ASA Physical Status Classification
- Surgery for traumatic brain injury or acute hemorrhagic stroke
- Awake brain surgery
- Osmotherapy before surgery (with the exception of prophylactic administration of osmotic agents according to institutional standards)
- Unavailability of hemodynamic monitoring data
- Cardiac arrhythmia with irregular cardiac rhythm
- Known hypersensitivity to the active substance or to any of the excipients of IMP (Investigational Medicinal Product)
- Pregnancy and lactation
Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.
Здоровые добровольцы: Нет
Дизайн исследования
- Распределение
- Рандомизированное
- Модель
- Параллельные группы
- Маскирование
- Двойное слепое
- Основная цель
- Лечение
Центры проведения
Список центров уточняется — проверьте первичный протокол.
Идентификаторы
NCT: NCT07101991 · CT0012025